StocksMedium•13 November 2026•
1 min read
Milestone Pharmaceuticals Cuts Costs 30% to Extend Cash Runway Through 2028
Key Facts
1Milestone Pharmaceuticals announced a cost-efficiency plan to reduce expenses by 30% and extend its cash runway into 2028.
Milestone Pharmaceuticals announced a cost-efficiency plan to reduce expenses by 30% and extend its cash runway into 2028. Investing.com reported that the strategy aims to ensure financial stability while supporting the development of Phase 3 clinical data for its AFib-RVR treatment.
MIST closed at $0.6552 on November 12, 2026, after reaching a day high of $0.707 and a low of $0.6425. The cost-reduction measures are intended to reduce immediate dilution risks and provide a longer timeframe to reach critical clinical milestones.